Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/JCMA.0000000000000352 http://scihub22266oqcxt.onion/10.1097/JCMA.0000000000000352 32433342!7493780!32433342     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Chin+Med+Assoc 2020 ; 83 (8): 704-709 Nephropedia Template TP {{tp|p=32433342|t=2020. Cardiovascular manifestation and treatment in COVID-19 |pdf=|usr=}}{{32433342}} gab.com Text Cardiovascular manifestation and treatment in COVID-19 JO: J Chin Med Assoc http://www.kidney.de/pget.php?&tw=1&pmid=32433342 #FOAvip The novel coronavirus disease 2019 (COVID-19), with first presentation of atypical pneumonia, has spread rapidly from Wuhan, China, on December 12, 2019 to over 200 countries, caused 2 310 572 infected individuals and 158 691 mortalities, updated on April 19, 2020. Many studies have published timely to help global healthcare workers to understand and control the disease. Vulnerable patients with risk factors such as elderly, cardiovascular diseases (eg, hypertension, coronary disease, or cardiomyopathy), diabetes, and chronic kidney disease have worse outcomes after COVID-19 infection. COVID-19 could directly cause cardiovascular injuries such as pericarditis, myocarditis, myocardial infarction, heart failure, arrhythmias, or thromboembolic events, which urge cardiologists to be involved in the frontline to practice. Here, we provide a review of COVID-19 on cardiovascular system to assist clinical cardiologists to better understand the disease and being capable of providing comprehensive medical support. Twit Text FOAVip Cardiovascular manifestation and treatment in COVID-19 ????J Chin Med Assoc http://www.kidney.de/pget.php?&tw=1&pmid=32433342 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32433342 #FOAvip English Wikipedia <ref>{{Cite pmid|32433342}}</ref> Cardiovascular manifestation and treatment in COVID-19 #MMPMID32433342 Su YB; Kuo MJ; Lin TY; Chien CS; Yang YP; Chou SJ; Leu HB J Chin Med Assoc 2020[Aug]; 83 (8): 704-709 PMID32433342show ga The novel coronavirus disease 2019 (COVID-19), with first presentation of atypical pneumonia, has spread rapidly from Wuhan, China, on December 12, 2019 to over 200 countries, caused 2 310 572 infected individuals and 158 691 mortalities, updated on April 19, 2020. Many studies have published timely to help global healthcare workers to understand and control the disease. Vulnerable patients with risk factors such as elderly, cardiovascular diseases (eg, hypertension, coronary disease, or cardiomyopathy), diabetes, and chronic kidney disease have worse outcomes after COVID-19 infection. COVID-19 could directly cause cardiovascular injuries such as pericarditis, myocarditis, myocardial infarction, heart failure, arrhythmias, or thromboembolic events, which urge cardiologists to be involved in the frontline to practice. Here, we provide a review of COVID-19 on cardiovascular system to assist clinical cardiologists to better understand the disease and being capable of providing comprehensive medical support. |*Betacoronavirus[MESH] |Anticoagulants/therapeutic use[MESH] |Antiviral Agents/therapeutic use[MESH] |COVID-19[MESH] |Cardiovascular Diseases/*etiology[MESH] |Coronavirus Infections/*complications/*drug therapy[MESH] |Humans[MESH] |Hydroxychloroquine/therapeutic use[MESH] |Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use[MESH] |Pandemics[MESH] |Pneumonia, Viral/*complications/*drug therapy[MESH]Cardiovascular manifestation and treatment in COVID-19 (epmc).pdf DeepDyve Pubget Overpricing